Aim immunotech submits pre-ind application to the fda for phase 2 clinical studies of ampligen as a potential early-onset therapeutic for covid-19

Aim has reached multiple major milestones demonstrating strong progress in developing its covid-19 portfolio aim has reached multiple major milestones demonstrating strong progress in developing its covid-19 portfolio
AIM Ratings Summary
AIM Quant Ranking